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ABSTRACT
Thyroid cancer is the most common endocrine malignancy with increasing 
incidence worldwide. 
The majority of thyroid cancer cases are well differentiated with favorable 
outcome. However, undifferentiated thyroid cancers are one of the most lethal human 
malignancies because of their invasiveness, metastatization and refractoriness even 
to the most recently developed therapies.
In this study we show for the first time a significant hyperactivation of ROCK/
HDAC6 pathway in thyroid cancer tissues, and its negative correlation with p53 DNA 
binding ability.
We demonstrate that a small compound, SP600125 (SP), is able to induce cell 
death selectively in undifferentiated thyroid cancer cell lines by specifically acting 
on the pathogenic pathways of cancer development. In detail, SP acts on the ROCK/
HDAC6 pathway involved in dedifferentiation and invasiveness of undifferentiated 
human cancers, by restoring its physiological activity level. As main consequence, 
cancer cell migration is inhibited and, at the same time, cell death is induced through 
the mitotic catastrophe. Moreover, SP exerts a preferential action on the mutant 
p53 by increasing its DNA binding ability. In TP53-mutant cells that survive mitotic 
catastrophe this process results in p21 induction and eventually lead to premature 
senescence. In conclusion, SP has been proved to be able to simultaneously block cell 
replication and migration, the two main processes involved in cancer development 
and dissemination, making it an ideal candidate for developing new drugs against 
anaplastic thyroid cancer.
INTRODUCTION
Thyroid cancer is the most common endocrine 
malignancy and its incidence is constantly increasing 
worldwide [1-3]. Although well-differentiated cancers 
(WDTCs) with good prognosis and favourable outcome 
constitute the large majority of thyroid cancers, the 
poorly differentiated (PDTCs) and anaplastic (ATCs) 
ones account for a significant portion of the morbidity and 
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mortality due to thyroid cancer [1, 4]. 
The pathogenesis of thyroid cancers is characterized 
by sequential accumulation of different genetic alterations. 
In particular, development of either PDTCs or ATCs 
results from genomic instability and accumulation of 
multiple aberrations leading to cell cycle deregulation 
and acquisition of anchorage-independent growth. These 
alterations are known to be responsible for the aggressive 
clinical features of these lethal tumors that are resistant to 
radioiodine, to conventional chemotherapy and external 
radiation, and even to tyrosine-kinase inhibitors (TKI) [1, 
5-7].
In the last decades, numerous alterations in proteins 
involved in thyroid cancer dedifferentiation process, 
including RAS, ALK, β-catenin and p53, have been 
identified [8-10]. In particular, mutations in β-catenin and 
p53 genes are almost absent in WDTCs but can be found 
respectively in up to 60% and 80% of ATCs [5].
In the present study, we explore the efficacy of a 
small compound, SP600125 (SP) in counteracting the 
aggressive tumorigenic behavior of undifferentiated 
thyroid cancer cells. 
SP is a reversible ATP-competitive multikinase 
inhibitor with recently discovered intriguing anticancer 
properties. It was shown that SP modifies cell cycle 
progression and causes endoreduplication with preferential 
activity against p53 null cells [11-13], induces p53-
independent apoptosis and cell cycle arrest [14-15] and 
increases cell sensitivity to various anti-proliferative drugs 
[16-17]. All of the reported mechanisms of action make SP 
an ideal candidate for developing new therapies against 
aggressive cancers, such as ATCs. However, most of the 
previously described SP actions imply a lack of target 
specificity that would undermine any further clinical 
development as anticancer treatment.
Here we describe for the first time a remarkable 
SP selectivity against cancer cells harboring TP53 point 
mutations and concomitant hyper-activation of Rho 
associated kinase (ROCK). We demonstrate that SP 
induces cell death and migration inhibition through the 
activation of mutant p53 and concomitant ROCK/HDAC6 
pathway inhibition. 
Moreover we provide new insights about the 
relationship between p53 inactivation and ROCK 
hyperactivation in thyroid cancer.
It has recently been reported tha loss of p53 results 
in hyperactivation of RhoA/ROCK pathway and this can 
lead to increased invasiveness [18-20]. In agreement 
with these findings our results shows for the first time an 
increase of ROCK activity in PTDCs and a strong inverse 
correlation between p53 DNA binding ability and ROCK 
activity in thyroid cancer tissues and cell lines.
The relevance and the potential impact of our 
findings are underlined by recent studies emphasizing 
the importance of p53 targeted therapy both in preclinical 
and clinical settings [21-23]. Furthermore they highlight 
the role of ROCK kinases in cancer cell invasion, in 
accordance with the recent clinical trials with ROCK-
targeting compounds [24-26].
RESULTS 
SP inhibits cell proliferation in a p53 dependent 
way
SP anti-proliferative effects were assessed in vitro 
on a normal thyroid derived cell line and seven thyroid 
cancer cell lines (Figure 1A) with genetic alterations 
typical of different thyroid cancer subtypes such as 
BRAFV600E variant, RET/PTC translocation, PI3K 
pathway hyperactivation and TP53 point mutations (see 
Supplemental Material and Methods). In accordance 
with previously published data [13], analysis of growth 
inhibition curves revealed that, at concentrations equal 
or higher than 30 μM, SP is highly effective against 
poorly differentiated cells that lack p53 activity (Figure 
1B). Moreover we show for the first time a preferential 
activity of low dose SP treatment on cells with missense 
inactivating TP53 alterations versus TP53-null ones. The 
selectivity against p53 mutant cells became even more 
apparent at concentrations of 10 μM or lower (Figure 
1B). The relative amounts of p53 protein in our cell lines 
was confirmed by western blot analysis (Figure 1C). 
Importantly, no significant association between BRAF or 
PI3K pathways hyperactivation and SP antiproliferative 
effects was found (Supplementary Table 1).
The concentrations of 10 and 20 μM were thus 
chosen for further investigations.
SP induces premature senescence through the 
p53/p21 pathway
Up to date, there are contrasting reports about p53 
involvement in the SP mechanism of action [11, 13-15, 
27]. To elucidate this point, three cell lines representing 
different TP53 status were chosen for further examination: 
the TP53 wild-type TPC1, the TP53 p.P152L mutant HTC/
C3, and the p53 pseudo-null SW1736.
The investigation of p53 levels and post-translational 
modification showed that 10 μM SP treatment leads to p53 
phosphorylation at Serine 15 and acetylation at Lysine 382 
only in HTC/C3 cells whereas no significant modifications 
were detected in TPC1 cells; a significant increase in p53 
levels, compatible with p53 activation and stabilization, 
was detected in HTC/C3 cells (Figure 2A and 2B), as these 
modification deeply affect p53 half-life and activity [28]; 
the fact that after SP treatment they were induced only in 
the p53 mutated cell lines made this pathway noteworthy 
of further investigations.
One of the main mechanisms of mutant p53 
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inactivation is the retention in cytoplasm, as most of p53 
post-translational modifications take place in the nucleus 
[28]. Immunofluorescence experiments showed that 10 
μM SP treatment leads to p53 nuclear translocation only 
in HTC/C3 cells whereas no significant translocation 
could be detected in TPC1 cells (Figure 2C). In HTC/C3 
cells these results were confirmed by cellular fractioning 
experiments, showing a significant increase in the p53 
nuclear fraction (Figure 2D). Moreover, a significant 
increase in p53 Serine 15 phosphorylation and Lysine 
382 acetylation was found only in the nuclear fraction 
of HTC/C3 cells (Figure 2D and 2E). In accordance with 
the detected post-translational modifications, an increase 
in p53 DNA binding activity was detected in HTC/C3 
cells after SP treatment, whereas no similar changes were 
observed in TPC1 cells (Figure 2F).
These results suggested that not only SP treatment 
is able to induce nuclear translocation of the mutant p53, 
but also promotes its functional activation. Therefore, the 
effects of SP treatment on the p53-downstream effector 
p21 were investigated either without or in the presence 
of Ischemin. This is a synthetic suppressor of p53 
transcriptional activity through the inhibition of its binding 
to the cofactor CBP after Lysine 382 acetylation [29].
We found that exposure to SP leads to a significant 
increase in p21 level only in HTC/C3 cells. This increase 
is, at least partially, dependent on p53 activity, as pre-
incubation with Ischemin significantly reverted p21 
induction (Figure 3A). Moreover, inhibition of p53 activity 
partially reduced the anti-proliferative effect of SP on 
HTC/C3 cells (Figure 3B), supporting the involvement of 
p53/p21 pathway modulation in SP mechanism of action.
In order to investigate the unknown mechanisms of 
p21 induction after SP treatment [11, 14, 30], 43 kinases 
and 2 related total proteins were simultaneously analyzed 
with Human Phospho-Kinase Antibody Array in HTC/
C3 cells. Significant changes in the level of β-catenin 
and other proteins involved in cell migration and growth 
control were detected after 60 hours of incubation with 
10 μM SP (Supplementary Figure 1, Supplementary 
Table 2). After 96 hours of treatment, the only 
modifications conserving the level of significance were 
p53 phosphorylation at Serine 15, FAK phosphorylation 
at Tyrosine 397 and β-catenin increases (Supplementary 
Figure 1, Supplementary Table 2).
One of the main consequences of p53/p21 pathway 
activation is the induction of cellular senescence. In fact 
TP53 mutant cells surviving 96 hours of SP treatment 
Figure 1: Antiproliferative effect of SP on distinct thyroid cancer cell lines with different TP53 status. Cell lines were 
exposed to different concentrations of SP or equal amount of DMSO for 96 hours and growth inhibition was assessed with MTT assay. A. 
Growth curves of the cell lines showing different degrees of inhibition. B. SP effects on the cell lines grouped by p53 status. C. Western 
blot confirming the differential expression of p53 in our cell lines; actin was used as loading control. MUT, p53 missense mutant, HTC/C3, 
Hth74 and SW579 cells; NULL, p53 pseudo-null, SW1736 and FRO cells; WT, p53 wild type, NTHY-ORI 3-1, TPC1 and K1 cells. ***p 
< 0.001, **p < 0.01 vs. WT, ###p < 0.001 vs. MUT.
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Figure 2: SP induces p53 nuclear translocation and activation in HTC/C3 cells. HTC/C3, TPC1 and SW1736 cells were 
incubated with 10 μM SP (SP10) or equivalent amount of DMSO (CTRL) for 96 hours; p53 nuclear translocation, its activating post-
translational modifications and DNA binding capacity was examined. A. Representative images of whole cell lysates western blots 
showing the levels of Ser 15 phosphorylated (P-p53), Lys 382 acetylated (Ac-p53) and total p53; actin was used as loading control. B. 
Densitometric analysis of whole cell lysates western blots. C. Confocal microscopy images showing changes in p53 (green staining) 
subcellular localization following SP treatment. DAPI (blue staining) was used as nuclear marker. Scalebars: 30 μm. D. Representative 
images of western blots of the nuclear (NUCL) and cytosolic (CYTO) extracts of HTC/C3 cells. The amount of Ser 15 phosphorylated 
(P-p53), Lys 382 acetylated (Ac-p53) and total p53 was examined. Actin was used as loading control, PARP was used as nuclear marker 
and GAPDH was used as cytoplasmic marker. E. Densitometric analysis of the western blots of the HTC/C3 subcellular fractions. F. SP-
induced changes in the DNA binding capacity of p53 in the two model cell lines expressing p53 protein.. *p < 0.05, **p < 0.01, ***p < 
0.001 vs. control.
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Figure 3: activated p53 induces senescence through its effector p21. Cells were incubated with 10 μM SP either in the presence of 
or without p53 inhibitor Ischemin (IS, 10 μM, subtoxical concentration determined in TPC1 cells) for 96 hours followed by the assessment 
of p21 expression, growth inhibition, morphological changes and senescence induction. Corresponding amounts of DMSO (CTRL) or 
Ischemin (IS) alone were used as controls. In the panel A and B, the p21 expression and the growth inhibition data are aligned with the 
respective treatment scheme below the bar diagram of growth inhibition. A. Representative images of western blots and their quantification 
illustrating the effect of SP and Ischemin treatment on p21 expression; actin was used as loading control B. Differential effects of Ischemin 
on the SP-induced growth inhibition in HTC/C3, TPC1 and SW1736 cells. C. SP-induced morphological changes and senescence (detected 
as blue senescence-specific X-gal staining - arrowheads) are reverted by Ischemin treatment in HTC/C3 cells. **p < 0.01, ***p < 0.001 vs. 
control; ###p < 0.001 vs. SP treated cells.
Figure 4: SP induces mitotic alterations in sensible cells. Cells were incubated with 10 μM (SP10) and 20 μM (SP20) SP or equal 
amount of DMSO (CTRL) for 72 hours and mitosis were analyzed with confocal microscopy. A. percentages of mitotic cells per microscopy 
field. B. percentages of normal, abnormal and multipolar mitosis. C. Representative 3D reconstructions from confocal images of normal 
mitotic figures in DMSO treated (CTRL) and abnormal mitotic figures in SP treated HTC/C3 cells. Staining shows Ser 10 Phospho-Histone 
H3 (red) and mitotic spindle (tubulin, green); DNA was labeled with DAPI (blue). *p < 0.05, **p < 0.01, ***p < 0.001 vs. control.
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appeared flattened, bigger, with increased amount of 
cytoplasmic vacuoles and dishomogeneous content. 
Up to 20% of the surviving HTC/C3 cells showed the 
senescence-specific X-gal staining. These effects were 
abolished by inhibition of p53 transcriptional activity 
through Ischemin pre-treatment (Figure 3C).
The presence of nuclear abnormalities such as 
heterochromatic foci, multinucleation and nuclear 
blebbing, lysosomal compartment expansion and positive 
γ-H2A.X staining in a large fraction of SP treated HTC/
C3 cells (Supplementary Figure 2) confirmed the presence 
of cellular senescence [31-32]. To date, increases in cell 
dimensions and in p21 expression following SP treatment 
have been occasionally reported [27, 33]. On the other 
hand, SP-induced p53-dependent premature senescence 
has never been reported. These data support that mutant 
p53 reactivation and senescence induction may contribute 
to the overall antiproliferative effect of SP.
Figure 5: SP alters microtubule architecture in a dose-dependent manner. The effect of SP on tubulin polymerization and 
acetylation was analyzed. A. Representative images of western blots of polymeric and monomeric tubulin fractions and their acetylation 
levels at Lys 40 following treatment with 10 μM SP up to 72 hours. B. Quantification of polymeric and monomeric tubulin acetylation 
levels. C. Quantification of the relative amounts of tubulin fractions. D. Confocal images of whole cell acquisitions (left columns) and 
relative 4X magnification details (right columns) showing acetylated microtubules architecture after DMSO (CTRL), 10 μM (SP10) and 20 
μM (SP20) SP incubation for 72 hours. Acetylated microtubule network, green staining; nuclei labeled with DAPI, blue staining; scalebars: 
30 μm. *p < 0.05, **p < 0.01, ***p < 0.001 vs day 0.
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SP induces cell death through mitotic catastrophe
The activation of p53/p21 pathway is responsible 
for SP cytostatic action by inducing premature senescence 
in cells which survived SP treatment; however the 
exact mechanism by which low doses of SP exert 
cytotoxic actions remains elusive. It has been reported 
previously that SP inhibits distinct kinases involved in 
cell cycle regulation and endoreduplication [11-12, 34]. 
We investigated whether SP is able to induce mitotic 
alterations in our cell lines.
Our results show that SP significantly affects mitosis 
in HTC/C3 cells and, to a lesser extent, in SW1736 cells, 
starting from 48 hours of incubation. In addition to the 
reduction in the frequency of mitotic cells (Figure 4A), 
morphological analysis of mitotic figures revealed an 
increase in the percentage of abnormal and multipolar 
mitotic forms (Figure 4B and 4C), defects that usually 
lead to mitotic slippage and aberrant division. No similar 
alterations were detected in TPC1 cells. Considering that 
aberrant mitosis and unbalanced DNA content can lead 
to death through mitotic catastrophe or to premature 
senescence, we hypothesize that mitotic cell death is the 
main anti-proliferative mechanism of SP, while induction 
of premature senescence in cells surviving the cytotoxic 
action is a later event and a crucial additional property 
that starts configuring SP as a pleiotropic anticancer agent.
SP effects are the result of alterations in 
microtubules network
High concentrations SP were shown to induce 
tubulin polymerization in vitro [33]. Microtubule poisons 
are well known anticancer drugs causing primary failure in 
mitosis progression and mitotic cell death with a stronger 
effect in p53 deficient cells [35-37]. Hence the effect of 
SP on the microtubule network organization of the cells 
was examined. A semi-quantitative tubulin fractionation 
assay revealed that SP induces a significant increase in 
tubulin polymerization in p53-mutant and pseudo-null 
cells (Figure 5A and C) together with a consistent increase 
in its acetylation at Lysine 40 (Figure 5A and B). This 
modification is usually found on stable microtubules but 
can result in mitosis block or abnormal chromosome 
segregation, when present at supraphysiological levels. 
Confocal microscopy revealed a complete upheaval of 
normal microtubule architecture in HTC/C3 cells. While 
the typical polarized acetylated fibers emerging from 
the microtubule-organizing center (MTOC) were clearly 
recognizable in untreated cells, the microtubules appeared 
thicker, bundle-like, widespread through the cytosol 
without an organizing center and completely unrelated 
to the nucleus after SP treatment. Importantly, only 
minor alterations were detected in TPC1 cells while an 
intermediate effect was detected in SW1736 cells (Figure 
5D) Therefore, alterations in tubulin dynamics may 
represent one of the main effects of SP, and elucidation of 
the exact mechanisms by which SP induces microtubule 
alterations represents a key point for its further 
development as anticancer drug.
SP exerts its main effects through direct inhibition 
of ROCK/HDAC6 pathway
In a previous screening, SP significantly inhibited 
the activity of ROCK [38], a kinase recently described 
to control tubulin and β-catenin stability through their 
main deacetylating enzyme HDAC6 [39-41]. Importantly, 
both enzymes are involved in cancer invasiveness and 
metastasization, and their activity was found to be 
increased in several undifferentiated cancers [24-25, 42-
45]. 
Therefore, we first confirmed the dose dependent 
Table 1: Genetic and clinical features of the human tumors samples.
Patients Histological data Genetic analyses Relevant clinical dataBRAF TP53 TERT
4 Papillary, pT3N1b WT WT nd WDTC, persistent disease, lung metasstasis
5 Papillary, pT1Nx p.V600E WT nd WDTC, cured
6 Papillary, pT3N0 p.V600E WT WT WDTC, cured
7 PDTC, pT4aN1 WT WT nd External radiotherapy, surgery for endotracheal recurrence, persistent disease
8 PDTC, pT3N1 p.V600E WT p.C228T Biochemical persistence 
9 PDTC, pT3N1b WT c.920-2A>G WT
Resistant to tyrosine-kinase inhibitor, disease-
related death at 26 years
10 PDTC, pT4aN1b p.V600E WT WT Persistent disease, local recurrence
11 PDTC, pT4aNx WT WT WT Persistent disease, lost at follow-up
12 PDTC, pT4aN1b WT WT nd Local recurrence, disease-related death at 77 years
The table summarize the histological, genetic and clinical data of patients with thyroid malignancies.
WDTC, well differentiated thyroid cancer; PDTC, poorly differentiated thyroid cancer; nd, not done.
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inhibitory effect of SP on the ROCK activity in a cell-
free enzyme inhibition assay (Figure 6A). Subsequently, 
basal ROCK activity was examined, showing that cell 
lines derived from undifferentiated thyroid cancers 
have a significantly higher activity than those derived 
from thyrocytes, a tendency accurately reflected by our 
model cell lines (Figure 6B). Noticeably, in HTC/C3 and 
SW1736 cells 10μM SP could counteract and reduce 
the ROCK activity to the level of WDTCs, whereas the 
inhibition was considerably lower in TPC1 cells (Figure 
6C). 
As a second step, we examined whether these 
results were reflected by the downstream pathway. Indeed, 
variations in cytoplasmic HDACs activity reflected the 
ROCK ones. The basal cytoplasmic HDACs activity in 
HTC/C3 and SW1736 was higher than in TPC1, and SP 
treatment exerted a significant inhibitory effect (Figure 
6D).
In particular, ROCK regulates the activity of 
HDAC6 through direct phosphorylation of TPPP1. TPPP1/
HDAC6 interaction results in the inhibition of HDAC6 
activity while TPPP1 phosphorylation causes HDAC6 
release and activation. HDAC6 then regulates microtubule 
and β-catenin stability [40]. 
Co-immunoprecipitation experiments showed 
that SP treatment significantly increases the interactions 
between TPPP1 and HDAC6 (Figure 6E), a modification 
accompanied by a significant enhancement of the 
acetylation of β-catenin (Figure 6E) and tubulin 
(previously reported in Figure 5A, 5B and 5D).
In addition, further important consequences of 
the ROCK/HDAC6 pathway inhibition include the 
impairment of cell migration and invasiveness [39-40, 
46-47]. Therefore we examine if SP treatment influences 
these processes.
A Wound-Healing assay revealed that SP is able 
to actively inhibit undifferentiated cancer cell migration. 
After SP treatment, TPC1 cells replenished the scratch 
whereas no progression toward the free edge was achieved 
by HTC/C3 cells and only partial replenishment was seen 
Figure 6: SP acts through ROCK/HDAC6 pathway inhibition. Basal status of ROCK/HDAC6 pathway and SP-induced 
modifications were analyzed. A. Cell-free enzyme activity assay shows that SP directly inhibits ROCK in a dose-dependent manner. B. 
Quantification of basal ROCK activity in our thyroid cell lines. Statistical significance is shown for undifferentiated versus differentiated 
thyroid cancer cell mean values. C. Quantification of ROCK activity in HTC/C3, TPC1 and SW1736 cells after incubation with 10 μM SP 
(SP10) or equivalent amount of DMSO (CTRL) for 72 hours; 1 μM ROCK inhibitor Y27632 (Y1) was used as control. D. Quantification of 
cytoplasmic HDAC activity in HTC/C3, TPC1 and SW1736 cells after incubation with 10 μM SP (SP10) or equivalent amount of DMSO 
(CTRL) for 72 hours; 5 μM HDAC inhibitor Trichostatin A (TSA5) was used as control. E. Representative images of western blots showing 
total amount of HDAC6, TPPP1 and Lys 49 acetylated β-catenin (upper blots) and co-immunoprecipitation experiments (central and lower 
blots) after incubation of HTC/C3 cells with 10 μM SP (SP10) or equivalent amount of DMSO (CTRL) for 72 hours; actin was used as 
loading control. IP immunoprecipitated protein, IB immunoblot. *p < 0.05, ***p < 0.001.
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in SW1736 cells at 16 hours post wound (Figure 7A and 
7D). In agreement with these data, an invasion assay 
showed a significant inhibition by SP of cell invasivity 
potential in HTC/C3 and SW1736, while TPC1 showed 
a lower but unaltered invasiveness (Figure 7B and 7E). 
As last step, we investigated β-catenin localization 
because it can act as pro-proliferative factor when it 
is cleaved from the cell membrane and relocated to the 
nucleus. In both resting and migrating HTC/C3 cells, 
β-catenin is localized at the cell membrane (Figure 7C, 
arrowheads). Moreover, SP treatment enhanced β-catenin 
signal and inhibited its relocation from the intercellular 
adhesion surface toward the leading edge of cell migration 
as indicated by arrowheads (Figure 7C). Noteworthy, in 
none of the cited conditions we observed an increased 
nuclear staining for β-catenin.
ROCK pathway in human thyroid cancer and 
correlation with p53 activity
Since no data about ROCK involvement in 
thyroid cancer development are currently available, we 
collected 12 tissue samples from patients that underwent 
thyroidectomy for compressive multinodular goiter, 
PTC or PDTC (Table 1). Genetic screening revealed that 
patient 9 is heterozygous for TP53 c.920-2A > G, a variant 
causing alternative splicing of exon 9 and premature stop 
codon, while patients 5, 6, 8 and 10 resulted heterozygous 
for BRAFV600E variant, and patient 8 carried C228T TERT 
promoter mutation.
Western blot analysis of protein extracts showed 
variable alterations in p53 levels in all cancer samples, 
with significant increases at densitometry in PDTCs ones 
compared to goiters ones (7.671±1.198 vs. 1.989±0.2921, 
respectively, p < 0.01). Low molecular weight bands of 
approximately 40-46 kDa were detected only in PDTCs 
Figure 7: SP inhibits cellular migration and invasiveness. A. Representative images of wound-healing assays with 10 μM 
SP (SP10) or equivalent amount of DMSO (CTRL) treatment. Black marks indicate wound edges at 0 and 16 hours post wound. B. 
Representative images of crystal violet stained cells from invasion assays after 10 μM SP (SP10) or equivalent amount of DMSO (CTRL) 
treatment. C. Effects of 10 μM SP (SP10), 20 μM SP (SP20) or equivalent amount of DMSO (CTRL) treatment on β-catenin localization 
in migrating HTC/C3 cells and its details at higher magnification. Scalebars represent 30 μm throughout the figure and indicate free edge 
direction. Arrowheads indicate β-catenin staining at cell membrane leading edge (CTRL) and intercellular junction (SP treated). Staining 
shows β-catenin (green), nucleus (DAPI, blue) and cell membrane (WGA, red). D. Quantification of wound width in wound-healing assays. 
E. Quantification of invasivity by lower-chamber cells solubilization and absorbance reading. ###p < 0.001 vs. 0 hours post wound, ***p 
< 0.001 vs. CTRL.
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samples (Figure 8A). These bands likely represent 
truncated forms of p53 that are known to be overexpressed 
in a significant fraction of undifferentiated cancer cells 
[48-49].
Interestingly, the highest phosphorylation levels 
of a direct ROCK substrate, MYPT, were detected in the 
patient harbouring the p53 mutation. 
In addition, the plot of p53 DNA binding ability 
versus ROCK activity showed a strong negative 
correlation in thyroid tissue samples as well as in cell lines 
with a p-value of 0.0249 and 0.0329, respectively and 
Pearson’s r of -0.4995 and -0.7477, respectively (Figure 
8B) providing a suggestive coupling between the two main 
SP effects.
DISCUSSION
In the present study we provide preliminary data 
on ROCK pathway alterations in thyroid cancer and we 
prove that SP retains an intriguing pleiotropic potential as 
anticancer agent. 
SP appears highly effective against ATCs 
and PDTCs in vitro, two histotypes of highly lethal 
malignancies characterized by local invasion, regional and 
distant metastases, disease recurrence and refractoriness 
to currently available anticancer therapies, including 
conventional and new-generation compounds [1, 4]. 
Importantly, we show that SP is highly effective in 
blocking thyroid cancer cell growth and migration and 
in the induction of mitotic catastrophe through direct 
inhibition of ROCK, a kinase involved in the regulation 
of cell migration, microtubule dynamics and β-catenin 
turnover [39-40, 46, 50]. This mechanism of action may 
be particularly important in anticancer therapy considering 
that Rho/ROCK pathway is hyperactivated in different 
human neoplasia and its activity correlates with metastatic 
disease [24-25, 42-43, 51-52]. No data on Rho/ROCK 
activation in thyroid cancer were available until now as 
the only previous study claiming a possible involvement 
of this pathway was performed on ARO cells [53], 
Figure 8: p53 and ROCK activity in thyroid tissue samples. A. Representative images of western blots of thyroid tissue samples 
derived from multinodular goiters (GOITER), papillary thyroid cancers (PTC) and poorly differentiated thyroid cancers (PDTC) showing 
the relative amount of p53 and Thr 696 phosphorylated MYPT1 (P-MYPT) ; GAPDH was used as loading control. An aspecific band of 
approximately 70 kDa was detected by p53 antibody. B. p53 DNA binding ability plotted versus ROCK activity graph of thyroid tissue 
samples (white symbols) and cell lines (grey symbols) showing significant negative correlation. Differentiated samples are reported as 
circles while poorly differentiated and anaplastic samples are reported as squares.
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which are now known not to be of thyroid origin [54]. 
Here we show for the first time that ROCK pathway is 
hyperactivated in PDTCs with defective p53 activity. In 
fact those derived from PDTCs had the highest levels of 
ROCK activity, which was reduced to the level of WDTCs 
upon SP treatment.
In accordance with a previous work [39], inhibition 
of ROCK affected HDAC6 function. Here we show 
that this is mediated by an enhanced TPPP1-HDAC6 
interactions. These alterations can account for the 
observed tubulin hyperstabilization and consequent 
mitotic abnormalities. The inability to proceed through 
the mitotic process is one of the known possible causes of 
cell death, mainly through mitotic catastrophe induction, 
and possibly accounts for the largest part of the anti-
oncogenic effects of SP here described (Figure 9). Since 
an increasing literature background [24, 26, 39] report 
a strict relation between the inhibition of ROCK/TPP1/
HDAC6 pathway and cell motility alterations, it is likely 
that this inhibition can account for the inhibition of cell 
migration and invasion observed after SP treatment.
In addition, we provide new insights about the 
relationship between p53 inactivation and ROCK 
hyperactivation in thyroid cancer. In fact the highest 
ROCK activity was detected in the only PDTC with 
TP53 mutation. Interestingly, this tumor was particulartly 
aggressive (Table 1). Our results demonstrate a strong 
inverse correlation between p53 DNA binding ability 
and ROCK activity in both tissue samples and cell lines. 
These findings are in agreement with previous reports 
of RhoA/ROCK pathway hyperactivation and increased 
invasiveness in cells with loss of p53 activity [18, 20]. 
Thus, the SP strong inhibitory effect against ROCK can 
be considered as the sum of direct inhibition through 
kinase binding and indirect inhibition through p53 
pathway restoration. This perspective can also explain 
the differences observed among p53 mutated and p53 null 
ones, as in the latter the second mechanism of action is 
not possible. 
We also show here that premature senescence 
is induced by SP in the HTC/C3 cells harboring TP53 
inactivating missense mutations. Since premature 
senescence appears at later time points than mitotic 
catastrophe and affect SP survived cells, one hypothesis 
can be that it is a secondary mechanism developed 
by cells surviving the SP-induced polyploidy and cell 
death (Figure 9). It is conceivable that the nodal point 
of this event is its dependence on the reactivation of the 
expressed p53 variants. The reactivation process restores 
cell responsiveness to chromosomal aberrations induced 
by microtubule alterations and results in senescence 
induction. On the other hand, the reactivation of p53 
activity can trigger the so-called Oncogene-Induced 
Senescence (OIS). It has been demonstrated that the 
Figure 9: Proposed schematic representation of SP action. The scheme shows SP effects on sensitive cancer cells and supposed 
mechanisms of action as derived from the integration between experimental data and literature background. The alteration of ROCK/
HDAC6 pathways leads to tubulin abnormalities and this could be responsible of mitotic catastrophe in the major part of treated cells (~80 
%). Longer incubation with SP leads to induction of premature senescence through p53/p21 pathway activation in a significant amount of 
surviving cells (~15 %).
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constant MAPK intracellular signaling induced by RAS 
or RAF mutations causes OIS rather than malignant 
transformation when not accompanied by other 
fundamental alterations that disrupt cell cycle control. The 
restoration of p53 activity can thus inhibit cell proliferation 
by allowing the activation of OIS [32]. Interestingly, these 
processes have been demonstrated also in thyroid cancer 
models, mainly in relation to the presence of BRAFV600E 
alteration, one of the main target of new TKI anticancer 
therapies [7, 55-57]. The speculation about OIS induction 
after p53 activity restoration by SP is supported by the 
selectivity against cell lines harbouring p53 mutations and 
the lack of effects on wild type or p53 pseudo-null ones. 
Although the exact mechanism by which SP 
influences p53 activity still needs to be clarified, the 
differences in the growth inhibition may be partially 
dependent on the greater ROCK inhibition observed in 
HTC/C3 cells versus the p53 pseudo-null ones. In fact, 
as ROCK activity is enhanced by p53 alterations [18, 20], 
the restoration of p53 activity can negatively influence 
the ROCK one. The induction of senescence in HTC/
C3 surviving clones in contrast to the maintenance of 
the proliferation phenotype in SW1736 ones then adds 
further difference to the final growth inhibitory result of 
SP treatment. 
In conclusion, our studies brought new evidence of 
ROCK/HDAC6 pathway involvement in thyroid tumors 
aggressiveness.
By targeting this pathway and the well known p53 
alterations, SP inhibits cell replication and migration at 
the same time, the two major processes involved in cancer 
development and dissemination thus revealing novel 
anticancer effects of SP in highly aggressive thyroid 
cancer cells. These effects may render SP a potential 
therapeutic agent in undifferentiated malignancies.
MATERIALS AND METHODS
Chemicals
Cell culture reagents were purchased from Life 
Technologies. SP600125 (1,9-Pyrazoloanthrone), MTT 
(3-(4,5-Dimethyl-2-thiazolyl)-2,5-diphenyl-2-tetrazolium-
bromide), Monoclonal anti-β-Catenin antibody 6F9, 
Monoclonal Anti-α-Tubulin clone DM1A, Monoclonal 
Anti-Acetylated Tubulin Clone 6-11B-1 were purchased 
from Sigma-Aldrich. p53 antibody, Phospho-p53 (Ser46) 
antibody, p53 (1C12) Mouse mAb, p21 Waf1/Cip1 
(DCS60) Mouse mAb, p21 Waf1/Cip1 (12D1) Rabbit 
mAb, Acetyl-p53 (Lys382) antibody, Phospho-p53 
(Ser15), antibody, Phospho-Histone H2A.X 20E3 
antibody, HDAC6 D2E5 antibody and Acetyl- β-Catenin 
(Lys49) antibody were purchased from Cell Signaling 
Technologies. ProLong Gold Antifade Reagent with DAPI, 
Wheat Germ Agglutinin Alexa-Fluor 594 Conjugate, 
Alexa-fluor conjugated and HRP conjugated secondary 
antibodies were purchased from Life Technologies. 
Purified Mouse Anti-Actin Ab-5 was purchased from BD 
Biosciences. Ischemin (MS120) and P-MYPT antibody 
were purchased from Merk Millipore. Phospho-Histone 
H3 pSer10 Antibody, TPPP/p25 antibody, TPPP antibody, 
Restore Western Blot Stripping reagent were purchased 
from Thermo Scientific. Protein G sepharose was 
purchased from GE Healthcare Life Sciences.
Cell culture
Cell lines used as model of normal thyrocytes 
(NTHY-ORI 3-1), well differentiated thyroid cancer 
(TPC1, K1), poorly differentiated thyroid cancer (HTC/C3 
and SW579) and anaplastic thyroid cancer (FRO, SW1736 
and Hth74) were a kind gift of Dr. Italia Bongarzone 
(Milan, Italy). Cells were grown as monolayers in 100 
mm plastic culture dishes with appropriate medium 
supplemented with penicillin and streptomycin and kept 
in a humidified incubator at 37°C under 5 % CO2. Specific 
cell lines origins and pathogenetic alterations are reported 
as part of supplementary material and methods. All 
experiments were performed with cell lines in between 7th 
and 13th passage. All cell lines were routinely screened for 
mycoplasma contamination with MycoAlert Mycoplasma 
Detection Kit (Lonza).
Proliferation assay
Cell proliferation was evaluated utilizing the 
3-(4,5-dimetylthiazole-2-yl)-2,5-diphenyltetrazolium 
bromide (MTT) assay as described before [58]. On the 
day of the assay, MTT solution was added to each well 
to a final concentration of 0.5 mg/ml 3 hours before 
measurement. Formazan crystals were then solubilized in 
200μL of EtOH:DMSO 1:1 solution. Absorbance was red 
at 540 nm using ELx800 Absorbance Microplate Reader 
(BioTek).
Thyroid tissue samples
Thyroid tissues from benign goiters and malignant 
tumors were collected during surgery, immediately frozen 
and stored at −80 °C. All the patients gave informed 
consent for genetic analysis and tissue studies. All 
specimens were reviewed by a trained pathologist to 
confirm the diagnosis. Goiters were used as reference 
control. Tumors were classified and staged according to 
the 7th edition of the TNM staging (Table 1),
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DNA extraction and sequencing
Around 10 mg of tissue was cut from frozen 
samples. DNA Extraction was performed on cut samples 
with Wizard Genomic DNA Purification Kit (Promega) 
following manufacturer’s instruction.
Bidirectional Sanger sequencing of the genomic 
DNA from patients’ samples was performed in order 
to reveal potential mutations in the coding exons of the 
TP53 gene, of TERT and of exon 15 of the BRAF gene 
spanning the mutation hotspot at codon 600. Primers 
and detailed PCR protocol are reported in supplementary 
material and methods. PCR products were cleaned up with 
ExoSAP-IT (Affymetrix) according to the manufacturer’s 
protocol. Dye terminator cycle sequencing was performed 
with BigDye Terminator v3.1 Cycle Sequencing Kit 
(Life Technologies) according to the manufacturer’s 
instructions and, following gel filtration cleanup of the 
reaction products, sequencing was performed on Applied 
Biosystems 3500 Genetic Analyzer (Life Technologies).
Protein extraction and western blot analysis
Western Blot experiments were performed as 
previously reported [59]. For detection of Phospho-
proteins cells were lysed with SDS sample buffer (62.5 
mM Tris-HCl pH 6.8, 2% SDS) supplemented with 
protease and phosphatase inhibitors, immediately heated 
for 3 min at 95°C and sonicated. 
Cellular fractioning experiments were performed 
with NE-PER Nuclear and Cytoplasmic Extraction 
Reagents (Thermo Scientific) kit following the 
manufacturer’s instruction.
Around 10 mg of tissue samples were homogenized 
and lysed in RIPA buffer (10 mM Tris-HCl pH 7.5, 500 
mM NaCl, 0.1% SDS, 1% NP40, 1% Na-deoxycholate, 
2 mM EDTA) supplemented with protease inhibitors. 
After incubation on rocking platform for 30 minutes at 4°, 
samples were centrifuged at 15000g for 20 minutes at 4°C 
and supernatant was collected to new tubes. 
All samples were quantified and immediately stored 
at -80.
Protein extracts were separated on NuPage 4-12% 
Bis-Tris Gels (Life Technologies) and transferred with 
iBlot System (Life technologies). Co-Immunoprecipitation 
samples were separated on 4-20% Mini-PROTEAN TGX 
Precast Protein Gels (Biorad) and transferred with iBlot 
System (Life technologies)
Membranes were blocked with 5% milk TBS-T, 
probed overnight at 4°C with the indicated primary 
antibody and incubated with the appropriate HRP-
conjugated secondary antibody for 1 h at room 
temperature. Detection was performed using the ECL-
plus kit. Bands of interest were quantified using ImageJ 
software version 1.47.
p53 DNA binding assay
The assay was performed with p53 transcriptional 
factor assay kit (Cayman Chemicals) following 
manufacteur’s instruction on nuclear extracts obtained 
with NE-PER Nuclear and Cytoplasmic Extraction 
Reagents. Colorimetric reaction was red at 450nm with 
ELx800 Absorbance Microplate Reader (BioTek). 
Human phospho-kinase antibody array
43 kinases and 2 related total proteins were analyzed 
with Human Phospho-Kinase Antibody Array (R&D 
Systems) following manufacturer’s instructions.
Senescence assay
Senescence induction was assayed with Senescence 
Cells Histochemical Staining Kit (Sigma-Aldrich) 
following the manufacturer’s instruction. Six fields per 
well were acquired with Kodak Camera mounted on 
Olympus CK2 microscope with A10PL 10X objective.
Tubulin polymerization assay
Tubulin monomer (soluble) and polymer (insoluble) 
forms were separated by centrifugation in hypotonic buffer 
and relative amounts were analyzed by electrophoresis and 
Western blotting as previously described [60]. Briefly cells 
were washed twice with warm PBS and then lysed with 
100μl of hypotonic buffer (1 mM MgCl
2,
 2 mM EGTA, 
0.5% NP40, 20 mM Tris-HCl pH 6.8) plus freshly added 2 
mM PMSF and protease inhibitor cocktail for 10 minutes 
at 37˚C. Cells were collected in tubes and the particulate 
fraction was separated from the soluble cytosolic fraction 
by centrifugation at 14000g for 10 minutes. Surnatant 
containing the monomeric tubulin was immediately 
collected and transferred to a new tube while the pellet 
containing the polymeric form was resuspended in equal 
amount of hypotonic buffer. All samples were sonicated 
and analyzed by electrophoresis and western blotting as 
described above.
Immunofluorescence and confocal microscopy
For cell membrane visualization, living cells were 
incubated with 5 μg/ml Wheat Germ Agglutinin Alexa-
Fluor 594 Conjugate (Life Technologies) in PBS for 10 
minute at 37°C in 5% CO2 prior to samples fixation. 
Samples were washed three times with pre-warmed PBS 
and fixated by incubation for in pre-warmed 2% PFA 
in PBS 10 minutes. After washing with PBS cells were 
pearmeabilized with 0.2% Triton-X in PBS for 10 minutes 
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and then blocked with 5% goat serum PBS at room 
temperature for 1 hour. Samples were incubated over night 
at 4°C with primary antibody solution. On the following 
day cells were washed three times in PBS, and 1 hour 
incubation was performed with appropriated secondary 
antibody solution. Samples were mounted on microscope 
slides with 15 μl of ProLong Gold Antifade Reagent with 
DAPI (Life Technologies).
Images were acquired with Nikon EclipseTi-E 
inverted microscope with IMA10X Argon-ion laser 
System by Melles Griot; all images were acquired with 
CFI Plan Apo VC 60X Oil (Nikon) objective except those 
for mitotic index determination which were acquired 
with CFI Plan Apo VC 20X (Nikon) objective. For p53 
imaging single acquisition was performed on nuclear 
plane. For H2A.X foci whole nuclei were acquired with 
Z-series acquisition, 0.15 μm steps. For microtubules and 
migration imaging whole cells were acquired with Z-series 
acquisition, 0.15 μm steps; for mitosis whole cells were 
acquired with Z-series acquisition, 0.1 μm steps and 3D 
structure reconstucted with NIS-Elements AR software. 
Mitotic figures were classified following Gisselsson 
description [61] after staining with DAPI, anti-tubulin and 
anti-P-Histone H3 antibodies.
Wound healing assay
Confluent cells were scraped with a p200 
tip, washed with PBS and returned to control or SP 
supplemented medium. Images were acquired at 0 and 
16h post-wound with Kodak EasyShare C195 camera on 
Olympus CK2 microscope with A10PL 10X objective. 
Wound dimensions were quantified with ImageJ software 
version 1.47.
Invasion assay
Cell invasivity was assayed with CytoSelect 24-
Well Cell Invasion Assay (Cell Biolabs, Inc) following 
the manufacturer’s instruction with minor modifications 
previously described [62]. 5 individual fields per insert 
were acquired with Kodak EasyShare C195 camera on 
Olympus CK2 microscope with A20PL 20X objective. 
After imaging, crystal violet stained cells were solubilized 
and absorbance was red at 540 nm using ELx800 
Absorbance Microplate Reader (BioTek).
HDAC activity assay
On the day of the assay cell fractioning was 
performed with NE-PER Nuclear and Cytoplasmic 
Extraction Reagents. Cytosolic extracts were processed 
with Epigenase HDAC Activity/Inhibition Direct Assay 
Kit (Epigentek) following the manufacturer’s instructions. 
Colorimetric reaction was detected at 450nm using 
ELx800 Absorbance Microplate Reader (BioTek).
ROCK activity assay 
On the day of the assay cells or tissue samples were 
extracted with specific buffer (50 mM Tris-HCl pH 7.5, 0.1 
mM EGTA and 0.1% 2-mercaptoethanol) [63] and ROCK 
activity measured with Rho-associated Kinase (ROCK) 
Activity Assay (Millipore) following the manufacturer’s 
instructions. The same kit was used for direct activity 
inhibition measurement. ROCK kinase was incubated with 
increasing concentration of SP and constant concentrations 
of ATP and MgCl
2
. Colorimetric reaction was detected 
at 450nm using ELx800 Absorbance Microplate Reader 
(BioTek). 
Co-Immunoprecipitation
Co-Immunoprecipitation was performed as 
previously described [64], with minimal modifications.
HTC/C3 cells were lysed in buffer containing 50 
mM Tris–HCl (pH 7.4), 150mM NaCl, 1% Triton X-100 
supplemented with protease inhibitors. 500 μg of lysate 
was pre-cleared with 10 μL of Protein G sepharose beads 
for 1 hours at 4˚C in agitation. Cleared lysates were 
incubated with ~2 μg of appropriated primary antibodies 
overnight at 4˚C with agitation. The following day 100 
μl of Protein G sepharose beads were added and samples 
incubated at 4°C for 2 hours. Protein complexes were 
precipitated through centrifugation at 15000g for 10 
minutes, washed three times and boiled. Samples were 
centrifugated at 15000g for 10 minutes and surnatant 
was analyzed by electrophoresis and western blotting as 
described above.
Statistical analysis
Values are expressed as means ± SEM. Statistical 
analysis were performed with GraphPad Prism Software, 
version 5.04. Student’s t-test was performed for two 
variable comparison while one-way ANOVA followed 
by Bonferroni’s post-hoc test was used to evaluate 
statistical significance between more than two variables. 
All experiments were performed at least four times in 
duplicate, with the exception of Human Phospho-Kinase 
Antibody Array that was performed once and read in 
triplicate. 
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